Advertisement

Organisation › Details
Emergence Therapeutics AG
Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high-need cancers. Its lead program uses innovative linker technology and payload technology to target Nectin-4 – an important and validated target for a broad range of cancers. Furthermore, Emergence is actively exploring opportunities to develop further best- or first-in-class ADCs driven by therapeutic need. Emergence has entered into a licensing and collaboration agreement with SATT Sud-Est (the regional tech transfer office for Aix-Marseille Université, CNRS and Inserm) through which the Company has been granted exclusive rights to a set of anti-Nectin-4 antibodies developed by Dr. Marc Lopez at the Cancer Research Center of Marseille, France. SATT Sud-Est is also providing financial support to the Emergence program. Emergence has also entered into a licensing and collaboration agreement with Heidelberg Pharma Research GmbH, a subsidiary of Heidelberg Pharma AG (FWB: HPHA). Through this agreement Emergence has access to Heidelberg Pharma’s amanitin-based payloads and corresponding linkers (proprietary ATAC Technology). Heidelberg Pharma Research is also a founding investor in Emergence. Nectin-4 has been clinically validated as an ADC target by enfortumab vedotin, recently approved for the treatment of urothelial cancers by the US Food and Drug Administration. Nectin-4 is highly expressed by many different cancers and has a limited expression in healthy tissues, especially compared to many other ADC targets. Emergence is developing a new Nectin-4 ADC with the potential to be a best-in-class ADC. Emergence is led by a strong management team and is supported by a network of world-leading scientists who have contributed significantly to the field of immuno-oncology. The Company is backed by a strong syndicate of European investors including Bpifrance, Gründerfonds Ruhr, Heidelberg Pharma Research GmbH, High-Tech Gründerfonds, idinvest Partners, Kurma Partners and NRW.Bank. Emergence is based in Duisburg, Germany with a subsidiary in Marseille, France. *
![]() |
Start | 2019-11-26 established |
Group | Eli Lilly (Group) | |
![]() |
Industry | BIOTECH |
Industry 2 | antibody-drug conjugate (ADC) | |
![]() |
Person | Elands, Jacobus P. M. (Jack) (Adcytherix 202406 CEO + Co-Founder before Emergence Tx + Blink Biomedical + Amakem) |
Person 2 | Dehning, Carsten (Adcytherix 202406 CFO before Emergence Therapeutics + Albireo + DeveloGen) | |
![]() |
Region | Duisburg |
Country | Germany | |
Street | 210 Schifferstr. | |
City | 47059 Duisburg | |
Address record changed: 2022-09-17 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: High-Tech Gründerfonds Management GmbH. (11/25/20). "Press Release: Emergence Therapeutics Announces a Bumped-up Follow-on Seed Round Financing". | ||
Record changed: 2024-12-29 |
Advertisement

More documents for Eli Lilly (Group)
- [1] NanoSyrinx Ltd.. (9/10/24). "Press Release: NanoSyrinx Closes £10 Million GBP Financing and Appoints Dr. Edwin Moses as Chairman". Coventry....
- [2] Qiagen N.V.. (9/4/24). "Press Release: Qiagen and Lilly Collaborate to Support Development of a QIAstat-Dx IVD Panel that Identifies Patients at Risk for Developing Alzheimer’s disease". Venlo....
- [3] Haya Therapeutics SA. (9/4/24). "Press Release: Haya Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform". Lausanne & San Diego, CA....
- [4] Kurma Partners. (5/2/24). "Press Release: Kurma Partners Announces the Promotion of Hadrien Bouchez to the Position of Partner". Paris....
- [5] Eli Lilly and Company. (12/27/23). "Press Release: Lilly Completes Acquisition of Point Biopharma". Indianapolis, IN....
- [6] Eli Lilly and Company. (11/17/23). "Press Release: Lilly to Expand Injectable Manufacturing Capacity with Planned $2.5 Billion Site in Germany". Indianapolis, IN....
- [7] Eli Lilly and Company. (11/17/23). "Press Release: Lilly Extends Tender Offer to Acquire Point Biopharma to Dec. 1, 2023". Indianapolis, IN....
- [8] Mablink Bioscience SAS. (10/18/23). "Press Release: Mablink Bioscience Enters an Agreement to be Acquired by Lilly". Lyon....
- [9] Eli Lilly and Company. (10/3/23). "Press Release: Lilly to Acquire Point Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies". Indianapolis, IN....
- [10] Eckert & Ziegler AG. (9/25/23). "Press Release: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma". Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top